What insurance policy changes affect CPT 38232?

There are 29 tracked policy changes affecting CPT 38232, including updates from Aetna, Humana. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 38232?

Payers that have issued tracked updates for CPT 38232 include: Aetna, Humana.

How do I get notified when CPT 38232 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 38232. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 38232?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

38232 — Doctors collect bone marrow from your own body for medical treatment or testing purposes.: Insurance Policy Changes

38232 Insurance Policy Changes

CPT 38232, in plain terms, covers Doctors collect bone marrow from your own body for medical treatment or testing purposes. CPT 38232 is referenced in 29 tracked payer policy changes from Aetna and Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 38232 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2026-09-23)

Aetna·Identified Oct 4, 2026

Aetna has updated its Clinical Policy Bulletin 0627 (reviewed 2026-09-23) establishing medical necessity criteria for allogeneic hematopoietic cell transplantation (HCT) for aplastic anemia and other bone marrow failure syndromes. The policy clarifies coverage for specific diagnoses (severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, and congenital dyserythropoietic anemia) with defined clinical criteria, and explicitly states that autologous HCT for these indications remains experimental/investigational and is not covered.

38232 Insurance Policy Changes

Brentuximab Vedotin (Adcetris) (CPB 0823, reviewed 2026-02-24)

Age-Related Macular Degeneration (CPB 0765, reviewed 2026-01-14)

Neurogenic Bladder: Selected Treatments (CPB 0852, reviewed 2025-12-23)

Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)

Hematopoietic Stem Cell Transplantation - Medicare Advantage (Revised)

Waskyra (etuvetidigene autotemcel) - Medicare Advantage (New)

Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors (CPB 0496, reviewed 2026-08-06)

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma (CPB 0494, reviewed 2026-08-03)

Dry Eyes (CPB 0457, reviewed 2026-07-29)

Transmyocardial and Endovascular Laser Revascularization (CPB 0163, reviewed 2026-03-20)

Narsoplimab-wuug (Yartemlea) (CPB 1099, reviewed 27-2026-04)

Huntington's Disease (CPB 0614, reviewed 2026-02-25)

Plerixafor (CPB 0779, reviewed 2026-02-13)

Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia (CPB 0674, reviewed 2025-12-23)

Hematopoietic Cell Transplantation for Ovarian Cancer (CPB 0635, reviewed 2025-12-11)

Hematopoietic Cell Transplantation for Waldenstrom Macroglobulinemia (CPB 0833, reviewed 2025-12-09)

Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (CPB 0836, reviewed 2025-12-09)

Hematopoietic Stem Cell Transplantation - Medicare Advantage (Revised)

Code Compendium (Musculoskeletal and Neurologic) - Medicare Advantage (Revised)

Diabetic Neuropathy: Selected Treatments (CPB 0729, reviewed 2026-10-21)

Narsoplimab-wuug (Yartemlea) (CPB 1099, reviewed 2026-10-16)

Age-Related Macular Degeneration (CPB 0765, reviewed 2026-10-14)

Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia (CPB 0674, reviewed 2026-10-07)

Hematopoietic Cell Transplantation for Ovarian Cancer (CPB 0635, reviewed 2026-09-11)

Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2026-09-23)

Narsoplimab-wuug (Yartemlea) (CPB 1099)

Huntington's Disease (CPB 0614, reviewed 2026-09-24)

Marnetegragene Autotemcel (Kresladi) (CPB 1102, reviewed 13-2026-07)

Hematopoietic Cell Transplantation for Myelofibrosis (CPB 0838, reviewed 2025-12-09)